Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
AstraZeneca
Harvard Business School
Accenture
Johnson and Johnson
Baxter

Generated: September 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,686,786

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,686,786
Title:Dial-down mechanism for wind-up pen
Abstract: The present invention relates to a dial-down mechanism for an injection device comprising a torsion spring for assisting injection of a dose of medicament from the injection device, the dial-down mechanism comprising dial-up cam arranged to receive and engage with a dial-up key, wherein the dial-up cam and the dial-up key are adapted to, upon rotation of a dose setting member in a first direction, cooperate to strain the torsion spring of the injection device, and a dial-down cam arranged to receive and engage with a dial-down key, wherein the dial-down cam and the dial-down key are adapted to, upon rotation of the dose setting member in a second direction, cooperate to release the torsion spring of the injection device, the second rotation direction being opposite to the first rotation direction.
Inventor(s): Moller; Claus Schmidt (Fredensborg, DK), Enggaard; Christian Peter (Vejby, DK), Radmer; Bo (Hillerod, DK), Markussen; Tom Hede (Bagsv.ae butted.rd, DK)
Assignee: Novo Nordiks A/S (Bagsvaerd, DK)
Application Number:11/665,486
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,686,786
Patent Claim Types:
see list of patent claims
Device; Delivery;

Drugs Protected by US Patent 7,686,786

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novo Nordisk Inc LEVEMIR FLEXTOUCH insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536-005 Oct 31, 2013 RX Yes Yes   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,686,786

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04077900Oct 21, 2004
PCT Information
PCT FiledOctober 20, 2005PCT Application Number:PCT/EP2005/011285
PCT Publication Date:May 04, 2006PCT Publication Number: WO2006/045526

International Family Members for US Patent 7,686,786

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 444090   Try a Free Trial
Australia 2005298944   Try a Free Trial
Canada 2584760   Try a Free Trial
China 100571804   Try a Free Trial
China 101060874   Try a Free Trial
Germany 602005016952   Try a Free Trial
Denmark 1804865   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Citi
Harvard Business School
UBS
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.